EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSSFOG00015009037
Gene Symbol: NR3C2
3 Cross references
210 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSSFOG00015019861
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSSFOG00015021784
Gene Symbol: OPRD1B
1 Cross references
251 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSSFOG00015028982
Gene Symbol: OPRL1
1 Cross references
131 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSSFOG00015016672
Gene Symbol: OPRL1
3 Cross references
189 Possible Orthologues:

Oxysterols Receptor Lxr-Alpha-Like

Ensembl ID : ENSSFOG00015013662
Gene Symbol: LOC108938803
3 Cross references
389 Possible Orthologues:

Oxysterols Receptor Lxr-Alpha-Like

Ensembl ID : ENSSFOG00015024439
Gene Symbol: LOC108940795
3 Cross references
389 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSSFOG00015018895
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSSFOG00015006490
Gene Symbol: PAK4
3 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSSFOG00015014280
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSSFOG00015024815
Gene Symbol: PPARD
3 Cross references
351 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSSFOG00015001328
Gene Symbol: PPARG
3 Cross references
389 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).